Success Metrics

Active Trials

5(71%)

Phase Distribution

Ph phase_2

71%

Ph phase_1

29%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

2(28.6%)

Phase 2Efficacy & side effects

5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(6)

Other(1)

Detailed Status

Recruiting5

Not yet recruiting1

Suspended1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 12 (28.6%)

Phase 25 (71.4%)

Trials by Status

not_yet_recruiting114%

recruiting571%

suspended114%

Recent Activity

5 active trials

Showing 5 of 7

recruitingphase_2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447

not_yet_recruitingphase_2

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

NCT07447076

recruitingphase_1

5G-PEARL: Paxalisib in Malignant Brain Tumours

NCT07391215

recruitingphase_1

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

NCT06208657

suspendedphase_2

Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

NCT05183204

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT03970447Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Recruiting

NCT07447076Phase 2

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

Not Yet Recruiting

NCT07391215Phase 1

5G-PEARL: Paxalisib in Malignant Brain Tumours

Recruiting

NCT06208657Phase 1

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Recruiting

NCT05183204Phase 2

Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma

Suspended

NCT05009992Phase 2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Recruiting

NCT04906096Phase 2

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Recruiting

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7